NEW YORK — Biodesix said today that it has signed an agreement to acquire Oncimmune's US operations and the US rights to the firm's blood-based incidental pulmonary nodule test EarlyCDT Lung.
The test, which UK-based Oncimmune launched in the US in 2012, measures levels of seven auto-antibodies to tumor-associated antigens. It is designed to detect all forms of lung cancer at any stage.
Under the terms of the deal, Boulder, Colorado-based Biodesix will acquire the rights to EarlyCDT in the US and all of Oncimmune's US operations including its De Soto, Kansas-based CLIA lab, which is the sole US provider of EarlyCDT Lung. Biodesix said it will make undisclosed milestone payments to Oncimmune based on the achievement of certain commercial objectives, and that the companies will collaborate on additional lung cancer-focused efforts.
Additional terms were not disclosed.
"Our Nodify XL2 test is used to help rule-out malignancy in low- to moderate-risk incidental lung nodules," Biodesix CEO David Brunel said in a statement. "EarlyCDT Lung is a rule-in test for lung cancer risk, and a natural and important extension of our commitment to care in the early-disease setting."